Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer()()

Anthracyclines, such as doxorubicin, are used as first-line chemotherapeutics, usually in combination therapies, for the treatment of advanced breast cancer. While these drugs have been successful therapeutic options, their use is limited due to serious drug related toxicities and acquired tumor res...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasim, Mohamed S., Nessim, Carolyn, Villeneuve, Patrick J., Vanderhyden, Barbara C., Dimitroulakos, Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039300/
https://www.ncbi.nlm.nih.gov/pubmed/29940414
http://dx.doi.org/10.1016/j.tranon.2018.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039300/
https://www.ncbi.nlm.nih.gov/pubmed/29940414
http://dx.doi.org/10.1016/j.tranon.2018.06.001

Ejemplares similares